These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
261 related articles for article (PubMed ID: 17711608)
1. Yes, industry influence is excessive. Shah AA; Finucane TE Int Psychogeriatr; 2007 Dec; 19(6):1004-10; discussion 1014-20. PubMed ID: 17711608 [No Abstract] [Full Text] [Related]
2. Is the influence of the pharmaceutical industry on prescribing, research and publication in the field of psychogeriatrics excessive? - No. Bhattacharyya S; Burns A Int Psychogeriatr; 2007 Dec; 19(6):1010-4; discussion 1014-20. PubMed ID: 17711609 [No Abstract] [Full Text] [Related]
3. For debate: is the influence of the pharmaceutical industry on prescribing, research and publication in the field of psychogeriatrics excessive? Ames D Int Psychogeriatr; 2007 Dec; 19(6):1003. PubMed ID: 17711607 [No Abstract] [Full Text] [Related]
4. Drug research: marketing before evidence, sales before safety. Klemperer D Dtsch Arztebl Int; 2010 Apr; 107(16):277-8. PubMed ID: 20467552 [No Abstract] [Full Text] [Related]
5. For richer, for poorer, in sickness and in health: the entanglement of science and marketing. Smith GP Aust N Z J Psychiatry; 2012 Jun; 46(6):498-500. PubMed ID: 22679202 [No Abstract] [Full Text] [Related]
6. Conflicts of interest: part 1: Reconnecting the dots--reinterpreting industry-physician relations. Rosenbaum L N Engl J Med; 2015 May; 372(19):1860-4. PubMed ID: 25946288 [No Abstract] [Full Text] [Related]
8. Correspondence (letter to the editor): Wholesale accusations? Throm S Dtsch Arztebl Int; 2010 Sep; 107(38):669; author reply 673-4. PubMed ID: 20953255 [No Abstract] [Full Text] [Related]
9. Research dishonesty and conflict of interest. Frizelle F N Z Med J; 2002 Dec; 115(1167):U270. PubMed ID: 12552259 [No Abstract] [Full Text] [Related]
10. Comments on 'The potential for bias in the reporting of industry sponsored clinical trials' by Stephen Pyke et al. and 'Proposed best practice for statisticians in the reporting and publication of pharmaceutical industry sponsored clinical trials' by James Matcham et al. Pharmaceutical Statistics. Campbell MJ Pharm Stat; 2011; 10(1):80-1. PubMed ID: 21275038 [No Abstract] [Full Text] [Related]
11. Correspondence (letter to the editor): Trend gives cause for concern. Maier C; Zenz M Dtsch Arztebl Int; 2010 Sep; 107(38):670-1; author reply 673-4. PubMed ID: 20953257 [No Abstract] [Full Text] [Related]
12. Bias in the design, interpretation, and publication of industry-sponsored clinical research. Hammerschmidt D Minn Med; 2008 Jun; 91(6):46-7. PubMed ID: 18616022 [No Abstract] [Full Text] [Related]
13. Implications of pharmaceutical industry funding on clinical research. Lexchin JR Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137 [TBL] [Abstract][Full Text] [Related]
14. Drug company influence. Mittman D Am J Nurs; 2009 Mar; 109(3):14; author reply 14. PubMed ID: 19240469 [No Abstract] [Full Text] [Related]
15. Drug companies, doctors and disclosures. Tuorto S; Chan MK; Adusumilli PS Natl Med J India; 2004; 17(4):215-6. PubMed ID: 15372772 [No Abstract] [Full Text] [Related]
16. Big pharma and American psychiatry. Sharfstein SS J Nerv Ment Dis; 2008 Apr; 196(4):265-6. PubMed ID: 18414119 [No Abstract] [Full Text] [Related]
17. Correspondence (letter to the editor): Need for advice. Grass G; Mäder K Dtsch Arztebl Int; 2010 Sep; 107(38):672; author reply 673-4. PubMed ID: 20953261 [No Abstract] [Full Text] [Related]
18. The accuracy of psychiatric medication advertisements in medical journals. Spielmans GI; Thielges SA; Dent AL; Greenberg RP J Nerv Ment Dis; 2008 Apr; 196(4):267-73. PubMed ID: 18414120 [TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals and medical devices: business practices. Issue brief. Thomson Reuters/West Issue Brief Health Policy Track Serv; 2011 Jan; ():1-44. PubMed ID: 21374840 [No Abstract] [Full Text] [Related]